Pembrolizumab,Vibostolimab,Gebasaxturev,MK-4830,Favezelimab
Merck
['vibostolimab', 'melanoma', 'pembro']
neoadjuvant vibostolimab plus pembrolizumab has shown antitumor activity in a phase 1/2 trial of patients with stage iiib-d melanoma. presented at aacr 2023. #aacr23 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.